Community Practice Connections™: MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis

Community Practice Connections™: MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis is organized by Physicians' Education Resource, LLC (PER).

Release Date: January 31, 2020
Expiration Date: January 31, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This interactive, case-based online activity features commentary from leading clinical experts in MPN treatment: Ronald Hoffman, MD; Rami S. Komrokji, MD; Ann Mullally, MD; and Abdulraheem Yacoub, MD. Topics include the impact of histologic and molecular patient characteristics on treatment decision making, JAK-STAT inhibition and interferon therapy as clinical strategies, and a look at the evolving therapeutic landscape for patients with myeloproliferative neoplasms‎ (MPNs). Specifically, clinical cases examining appropriate treatment options for patients with varying degrees of risk with polycythemia vera (PV) and myelofibrosis (MF) are presented. The latest data from clinical trials investigating emerging agents and combination strategies across MPNs are applied to faculty discussion of pertinent clinical cases.

Benefits of Participating:
• Update your clinical approach through a discussion of the most up-to-date risk-scoring systems for MPNs in patients with varying risk levels
• Review best practices for management of patients with MPNs
• Learn how to evaluate patients for referral to clinical trials
• Hear top experts develop appropriate treatment plans for a variety of patients with MPNs

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Review recent updates in molecular diagnostics and their potential impact on clinical decision making in the management of MF and PV
• Explain the mechanistic rationale for overlap of MF and PV therapeutic approaches in the context of the current treatment landscape
• Assess data from recent clinical trials on emerging strategies for the treatment of MF and PV
• Discuss strategies to integrate recent trial findings into clinical practice to optimize decision making and care for patients with MF and PV